Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with de novo acute myeloid leukemia (AML). Mutated FLT3 variants are constitutively active kinases signaling via AKT kinase, MAP kinases, and STAT5. FLT3 inhibitors have been approved for the treatment of FLT3-mutated AML...

Descripción completa

Detalles Bibliográficos
Autores principales: Seipel, Katja, Graber, Carolyn, Flückiger, Laura, Bacher, Ulrike, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347059/
https://www.ncbi.nlm.nih.gov/pubmed/34360855
http://dx.doi.org/10.3390/ijms22158092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347059/
https://www.ncbi.nlm.nih.gov/pubmed/34360855
http://dx.doi.org/10.3390/ijms22158092

Ejemplares similares